IRVINE, Calif., Oct. 9, 2013 /PRNewswire/ -- In an effort to take the fight against heart disease worldwide, TriValley Group of Qatar announced that Dr. Douglas Harrington has accepted the position of Managing Director of its international operations. As such, Dr. Harrington will be leading the international expansion into a number of countries of a novel cardiac test that identifies individuals who are at risk of having a heart attack in the next 5 years. Dr. Harrington will maintain a United States office for TriValley Group.
Qatar Heart Lab Holdings (QHLH) is the investing arm of TriValley Group who holds the international distribution rights of the MIRISK and MIRISK VP™ cardiac tests. TriValley Group recently entered into a distribution and expansion pact covering 19 countries throughout the Middle East and Asia to roll out a network that will distribute the tests. These tests have demonstrated significant improvement in the identification of individuals at risk of heart attack. The governments and health care authorities in these regions are now taking a proactive approach to finding and implementing solutions to stop the increase in the heart disease epidemic.
Dr. Harrington stated "I am confident that we will have an impact on the reduction of heart disease as we expand world-wide. The unmet clinical need to identify at-risk individuals who are not detected by current practices has huge implications for preventive healthcare."About TriValley GroupTriValley is a distinguished group of companies and a leader in numerous spheres of Finance, Commercial, Industrial, Electromechanical, Healthcare, and Construction within the state of Qatar. The highly esteemed group is owned by H.E Sheikh Khalid Bin Jabor Mohamed Al Thani, a prominent member of the ruling family. About Qatar Heart Laboratory HoldingsQatar Heart Lab Holdings, (QHLH), is the investing arm of TriValley Group who holds the international distribution rights of the MIRISK and MIRISK VP™ cardiac tests that have demonstrated significant improvement in the identification of individuals at risk of heart attack. The Middle East and Asia have seen a steep rise in both obesity and diabetes, resulting in a parallel increase in cardiac disease and its complications in those societies. In the past decade, diabetic prevalence has reached more than 38 percent and obesity rates exceed 35 percent of the population in some Middle Eastern Countries. Qatar Heart Lab Holdings (QHLH) is dedicated to fight this global epidemic which remains the #1 killer worldwide. Najib Khoury email@example.com+974 44 21 5522 . 949.633.3772 SOURCE TriValley Group